Grant Number:	5U01CA195568-04 Interpret this number
Primary Investigator:	Cerhan, James
Organization:	Mayo Clinic Rochester
Project Title:	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Fiscal Year:	2018

 DESCRIPTION (provided by applicant): In 2014, an estimated 70,800 people in the US will be diagnosed with non-Hodgkin lymphoma (NHL), and 18,990 will die from this cancer. NHL incidence rates increased over the last half of the 20th century and only recently stabilized. In parallel, NHL survival rates began improving in the mid-1990s with the advent of improved treatment strategies, leading to the current 5-year survival rate of 69 percent. These trends have led to a growth in the number of NHL survivors, estimated at over 650,000 in 2010. To address the current and long-term unmet health needs of this growing patient population, we propose to establish the Lymphoma Epidemiology of Outcomes (LEO) cohort study, which will expand an ongoing cohort of over 4,000 NHL patients that was established in 2002. The goal of expanding this infrastructure to over 12,000 NHL patients is to support a broad research agenda aimed at identifying novel clinical, epidemiologic, host genetic, tumor, and treatment factors that significantly influence NHL prognosis and survivorship. To meet these goals, over the next 5 years we propose to: 1) Expand recruitment to six new centers, with a goal of recruiting 8,700 newly diagnosed NHL patients (including 1,000 African American and 1,400 Hispanic participants), for a total cohort of 12,900 patients (including 3,700 diffuse large B-cell and 3,30 follicular lymphomas); 2) Review all pathology diagnoses and build a NHL tumor bank that includes an H&E slide, a formalin-fixed, paraffin-embedded tissue samples, and extracted tumor DNA and RNA; 3) Collect a peripheral blood sample and bank DNA, serum, plasma and buffy coat in a central biorepository; 4) Annotate and harmonize all cases with clinical, epidemiologic, pathology and treatment data; 5) Prospectively follow patients in the cohort regularly to ascertain disease progression/relapse, retreatment, transformation, second cancers, survival (including cause of death), updated exposures, patient-reported outcomes (PROs), and other long-term health outcomes; and 6) Facilitate research projects that use this infrastructure and promote interactions with lymphoma clinical trial networks. We will achieve these aims through close coordination of each of the participating centers, supported by four cores (Administration; Clinical; Pathology & Biospecimens; and Biostatistics & Informatics). These cores will also conduct methodological research to enhance data collection, patient follow-up, biospecimen science and statistical modeling. The proposed LEO cohort infrastructure overcomes limitations of other study designs, is feasible, and will be used to improve diagnosis, risk stratification, treatment, and short and long-term management of NHL patients. The LEO investigators will leverage this resource to foster discovery and validation of novel biologic and clinical insights. LEO will be led by international leaders in clinical and epidemiologic research on NHL thereby driving the translation of new findings to the clinic and the population.




Risk of lymphoid malignancy associated with cancer predisposition genes.
Authors: Boddicker N.J. , Mwangi R. , Robinson D.P. , Allmer C. , Rosenthal A.C. , Habermann T.M. , Feldman A.L. , Rimsza L.M. , King R.L. , Larson M.C. , et al. .
Source: Blood Cancer Journal, 2025-04-19 00:00:00.0; 15(1), p. 71.
EPub date: 2025-04-19 00:00:00.0.
PMID: 40253392
Related Citations

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Authors: Yamshon S. , Koff J.L. , Larson M.C. , Kahl B.S. , Casulo C. , Lossos I.S. , Haddadi S. , Stanchina M. , Chihara D. , Ayers A. , et al. .
Source: American Journal Of Hematology, 2025-02-07 00:00:00.0; , .
EPub date: 2025-02-07 00:00:00.0.
PMID: 39918101
Related Citations

Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.
Authors: Bommier C. , Link B.K. , Gysbers B.J. , Maurer M.J. , Larson M.C. , Khurana A. , Wang Y. , Thompson C.A. , Chihara D. , Alderuccio J.P. , et al. .
Source: Blood Advances, 2024-12-10 00:00:00.0; 8(23), p. 5939-5948.
PMID: 39321424
Related Citations

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
Authors: Friedberg J.W. , Brady M.T. , Strawderman M. , Kahl B.S. , Lossos I.S. , Cohen J.B. , Reagan P.M. , Casulo C. , Averill B.L. , Baran A. , et al. .
Source: Eclinicalmedicine, 2024 Dec; 78, p. 102959.
EPub date: 2024-11-27 00:00:00.0.
PMID: 39677358
Related Citations

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis.
Authors: Abro B. , Maurer M.J. , Habermann T.M. , Burack W.R. , Chapman J.R. , Cohen J.B. , Friedberg J.W. , Inghirami G. , Kahl B.S. , Larson M.C. , et al. .
Source: Blood, 2024-11-07 00:00:00.0; 144(19), p. 2063-2066.
PMID: 39255410
Related Citations

DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas.
Authors: Hopper M.A. , Dropik A.R. , Walker J.S. , Novak J.P. , Laverty M.S. , Manske M.K. , Wu X. , Wenzl K. , Krull J.E. , Sarangi V. , et al. .
Source: Blood Cancer Journal, 2024-10-09 00:00:00.0; 14(1), p. 172.
EPub date: 2024-10-09 00:00:00.0.
PMID: 39384745
Related Citations

Transformation of marginal zone lymphoma to Hodgkin lymphoma.
Authors: Moalem K.N. , Alderuccio J.P. , Bommier C. , Habermann T. , Link B.K. , Cerhan J.R. , Florindez J. , Lossos I.S. .
Source: Blood Advances, 2024-09-10 00:00:00.0; 8(17), p. 4559-4562.
PMID: 39024508
Related Citations

Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis.
Authors: Florindez J.A. , Chihara D. , Reis I.M. , Lossos I.S. , Alderuccio J.P. .
Source: Blood Advances, 2024-08-27 00:00:00.0; 8(16), p. 4423-4432.
PMID: 38954843
Related Citations

Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
Authors: Khurana A. , Mwangi R. , Nastoupil L.J. , Reagan P.M. , Farooq U. , Romancik J.T. , McDonnell T.J. , Riska S.M. , Lossos L.S. , Kahl B.S. , et al. .
Source: Blood Advances, 2024-08-27 00:00:00.0; 8(16), p. 4414-4422.
PMID: 38991126
Related Citations

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
Authors: Stokes M.E. , Wenzl K. , Huang C.C. , Ortiz M. , Hsu C.C. , Maurer M.J. , Stong N. , Nakayama Y. , Wu L. , Chiu H. , et al. .
Source: Nature Communications, 2024-08-08 00:00:00.0; 15(1), p. 6790.
EPub date: 2024-08-08 00:00:00.0.
PMID: 39117654
Related Citations

Defining primary refractory large B-cell lymphoma.
Authors: Bock A.M. , Mwangi R. , Wang Y. , Khurana A. , Maurer M.J. , Ayers A. , Kahl B.S. , Martin P. , Cohen J.B. , Casulo C. , et al. .
Source: Blood Advances, 2024-07-09 00:00:00.0; 8(13), p. 3402-3415.
PMID: 38669353
Related Citations

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.
Authors: Wenzl K. , Stokes M.E. , Novak J.P. , Bock A.M. , Khan S. , Hopper M.A. , Krull J.E. , Dropik A.R. , Walker J.S. , Sarangi V. , et al. .
Source: Blood Cancer Journal, 2024-06-20 00:00:00.0; 14(1), p. 100.
EPub date: 2024-06-20 00:00:00.0.
PMID: 38902256
Related Citations

Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment.
Authors: Arcaini L. , Bommier C. , Alderuccio J.P. , Merli M. , Fabbri N. , Nizzoli M.E. , Maurer M.J. , Tarantino V. , Ferrero S. , Rattotti S. , et al. .
Source: Eclinicalmedicine, 2024 Jun; 72, p. 102592.
EPub date: 2024-04-11 00:00:00.0.
PMID: 38633575
Related Citations

Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
Authors: Bantilan K.S. , Smith A.N. , Maurer M.J. , Teruya-Feldstein J. , Matasar M.J. , Moskowitz A.J. , Straus D.J. , Noy A. , Palomba M.L. , Horwitz S.M. , et al. .
Source: Blood Advances, 2024-05-14 00:00:00.0; 8(9), p. 2172-2181.
PMID: 38271621
Related Citations

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning.
Authors: Tavolara T.E. , Niazi M.K.K. , Feldman A.L. , Jaye D.L. , Flowers C. , Cooper L.A.D. , Gurcan M.N. .
Source: Diagnostic Pathology, 2024-01-19 00:00:00.0; 19(1), p. 17.
EPub date: 2024-01-19 00:00:00.0.
PMID: 38243330
Related Citations

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Authors: Cerhan J.R. , Maurer M.J. , Link B.K. , Feldman A.L. , Habermann T.M. , Jaye D.L. , Burack W.R. , McDonnell T.J. , Vega F. , Chapman J.R. , et al. .
Source: American Journal Of Hematology, 2024-01-13 00:00:00.0; , .
EPub date: 2024-01-13 00:00:00.0.
PMID: 38217361
Related Citations

The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Authors: Cerhan J.R. , Maurer M.J. , Link B.K. , Feldman A.L. , Habermann T.M. , Jaye D.L. , Burack W.R. , McDonnell T.J. , Vega F. , Chapman J.R. , et al. .
Source: American Journal Of Hematology, 2024-01-13 00:00:00.0; , .
EPub date: 2024-01-13 00:00:00.0.
PMID: 38217361
Related Citations

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Authors: Alderuccio J.P. , Reis I.M. , Hamadani M. , Nachiappan M. , Leslom S. , Kahl B.S. , Ai W.Z. , Radford J. , Solh M. , Ardeshna K.M. , et al. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2024-01-05 00:00:00.0; 30(1), p. 139-149.
PMID: 37855688
Related Citations

Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Authors: Maurer M.J. , Casulo C. , Larson M.C. , Habermann T.M. , Lossos I.S. , Wang Y. , Nastoupil L.J. , Strouse C. , Chihara D. , Martin P. , et al. .
Source: Haematologica, 2023-11-30 00:00:00.0; , .
EPub date: 2023-11-30 00:00:00.0.
PMID: 38031804
Related Citations

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
Authors: Bock A.M. , Gile J.J. , Larson M.C. , Poonsombudlert K. , Tawfiq R.K. , Maliske S. , Maurer M.J. , Kabat B.F. , Paludo J. , Inwards D.J. , et al. .
Source: Blood Cancer Journal, 2023-11-13 00:00:00.0; 13(1), p. 169.
EPub date: 2023-11-13 00:00:00.0.
PMID: 37957158
Related Citations

Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Authors: Mastini C. , Campisi M. , Patrucco E. , Mura G. , Ferreira A. , Costa C. , Ambrogio C. , Germena G. , Martinengo C. , Peola S. , et al. .
Source: Science Translational Medicine, 2023-06-28 00:00:00.0; 15(702), p. eabo3826.
EPub date: 2023-06-28 00:00:00.0.
PMID: 37379367
Related Citations

Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas.
Authors: Hopper M.A. , Wenzl K. , Hartert K.T. , Krull J.E. , Dropik A.R. , Novak J.P. , Manske M.K. , Serres M.R. , Sarangi V. , Larson M.C. , et al. .
Source: Hematological Oncology, 2023-05-30 00:00:00.0; , .
EPub date: 2023-05-30 00:00:00.0.
PMID: 37254453
Related Citations

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
Authors: Correia C. , Maurer M.J. , McDonough S.J. , Schneider P.A. , Ross P.E. , Novak A.J. , Feldman A.L. , Cerhan J.R. , Slager S.L. , Witzig T.E. , et al. .
Source: Blood Cancer Journal, 2023-05-17 00:00:00.0; 13(1), p. 81.
EPub date: 2023-05-17 00:00:00.0.
PMID: 37193683
Related Citations

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
Authors: Alderuccio J.P. , Reis I.M. , Koff J.L. , Larson M.C. , Chihara D. , Zhao W. , Haddadi S. , Habermann T.M. , Martin P. , Chapman J.R. , et al. .
Source: Blood, 2023-04-13 00:00:00.0; 141(15), p. 1888-1893.
PMID: 36735908
Related Citations

Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Authors: Alhaj Moustafa M. , Borah B.J. , Moriarty J.P. , Dholakia R. , Jiang L. , Li K. , Witzig T.E. , Hoppe B.S. , Peterson J. , Cerhan J.R. , et al. .
Source: Clinical Lymphoma, Myeloma & Leukemia, 2023 Apr; 23(4), p. 259-265.
EPub date: 2023-01-26 00:00:00.0.
PMID: 36775698
Related Citations

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis.
Authors: Desai S.H. , Mwangi R. , Ng W.L. , King R.L. , Maurer M.J. , Cerhan J.R. , Feldman A.L. , Farooq U. , Mou E. , Habermann T.M. , et al. .
Source: Blood Advances, 2022-12-27 00:00:00.0; 6(24), p. 6180-6186.
PMID: 36170803
Related Citations

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Authors: Epperla N. , Switchenko J.M. , Bachanova V. , Gerson J.N. , Barta S.K. , Gordon M.J. , Danilov A.V. , Grover N.S. , Mathews S.P. , Burkart M. , et al. .
Source: Blood Advances, 2022-12-14 00:00:00.0; , .
EPub date: 2022-12-14 00:00:00.0.
PMID: 36516079
Related Citations

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
Authors: Desai S.H. , Mwangi R. , Smith A.N. , Maurer M.J. , Farooq U. , King R.L. , Cerhan J.R. , Feldman A.L. , Habermann T.M. , Thompson C.A. , et al. .
Source: Hematological Oncology, 2022-10-28 00:00:00.0; , .
EPub date: 2022-10-28 00:00:00.0.
PMID: 36305717
Related Citations

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.
Authors: Alderuccio J.P. , Reis I.M. , Habermann T.M. , Link B.K. , Thieblemont C. , Conconi A. , Larson M.C. , Cascione L. , Zhao W. , Cerhan J.R. , et al. .
Source: American Journal Of Hematology, 2022-09-03 00:00:00.0; , .
EPub date: 2022-09-03 00:00:00.0.
PMID: 36057138
Related Citations

A roadmap for clinical trial design in marginal zone lymphoma.
Authors: Alderuccio J.P. , Habermann T. , Kuker R. , Moskowitz C.H. , Zelenetz A.D. , Lossos I.S. .
Source: American Journal Of Hematology, 2022-08-28 00:00:00.0; , .
EPub date: 2022-08-28 00:00:00.0.
PMID: 36030403
Related Citations

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
Authors: Luan D. , Fatola T. , Toure A. , Flowers C.R. , Link B. , Friedberg J.W. , Cohen J.B. , Kahl B. , Lossos I.S. , Nastoupil L. , et al. .
Source: Blood Advances, 2022-08-09 00:00:00.0; 6(15), p. 4413-4423.
PMID: 35793440
Related Citations

Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.
Authors: Sidana S. , Allmer C. , Larson M.C. , Dueck A. , Yost K. , Warsame R. , Thanarajasingam G. , Cerhan J.R. , Paludo J. , Rajkumar S.V. , et al. .
Source: Jco Oncology Practice, 2022 Aug; 18(8), p. e1320-e1333.
EPub date: 2022-05-17 00:00:00.0.
PMID: 35580285
Related Citations

Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study.
Authors: Tun A. , Khurana A. , Mwangi R. , Link B.K. , Wang Y. , Feldman A. , Thompson C.A. , Novak A.J. , Villasboas J.C. , Thanarajasingam G. , et al. .
Source: Blood Advances, 2022-07-18 00:00:00.0; , .
EPub date: 2022-07-18 00:00:00.0.
PMID: 35849723
Related Citations

Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis.
Authors: Strouse C.S. , Larson M.C. , Ehlers S.L. , Yost K.J. , Maurer M.J. , Ansell S.M. , Inwards D.J. , Johnston P.B. , Micallef I.N. , Link B.K. , et al. .
Source: Jco Oncology Practice, 2022 Jul; 18(7), p. e1069-e1080.
EPub date: 2022-05-20 00:00:00.0.
PMID: 35594505
Related Citations

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
Authors: Desai S.H. , Pederson L. , LaPlant B. , Mwangi R. , Maurer M. , Young J.R. , Macon W.R. , King R.L. , Wang Y. , Cerhan J.R. , et al. .
Source: Blood Cancer Journal, 2022-05-03 00:00:00.0; 12(5), p. 78.
EPub date: 2022-05-03 00:00:00.0.
PMID: 35504884
Related Citations

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Authors: Casulo C. , Larson M.C. , Lunde J.J. , Habermann T.M. , Lossos I.S. , Wang Y. , Nastoupil L.J. , Strouse C. , Chihara D. , Martin P. , et al. .
Source: The Lancet. Haematology, 2022 Apr; 9(4), p. e289-e300.
PMID: 35358443
Related Citations

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Authors: Castellino A. , Wang Y. , Larson M.C. , Maurer M.J. , Link B.K. , Farooq U. , Feldman A.L. , Syrbu S.I. , Habermann T.M. , Paludo J. , et al. .
Source: Blood Advances, 2022-02-22 00:00:00.0; 6(4), p. 1350-1360.
PMID: 34662895
Related Citations

Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria.
Authors: King R.L. , Khurana A. , Mwangi R. , Fama A. , Ristow K.M. , Maurer M.J. , Macon W.R. , Ansell S.M. , Bennani N.N. , Kudva Y.C. , et al. .
Source: Hemasphere, 2021 Oct; 5(10), p. e640.
EPub date: 2021-09-06 00:00:00.0.
PMID: 34514344
Related Citations

Perceptions of clinical care and research among African-American patients with lymphoma.
Authors: Dance K.V. , Imbody C.B. , Chen L. , McNeill L. , Payne J.B. , Flowers C.R. .
Source: Leukemia & Lymphoma, 2021 08; 62(8), p. 1860-1868.
EPub date: 2021-02-28 00:00:00.0.
PMID: 33645400
Related Citations

The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.
Authors: Abeykoon J.P. , Hampel P.J. , King R.L. , Wood A.J. , Larson M.C. , Nowakowski K.E. , Zanwar S.S. , Dasari S. , Ruan G.J. , Ravindran A. , et al. .
Source: Haematologica, 2021-08-01 00:00:00.0; 106(8), p. 2261-2264.
EPub date: 2021-08-01 00:00:00.0.
PMID: 33657788
Related Citations

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.
Authors: Boddicker N.J. , Larson M.C. , Castellino A. , Herrmann J. , Inwards D.J. , Thanarajasingam G. , Maurer M.J. , Allmer C. , Witzig T.E. , Nowakowski G.S. , et al. .
Source: American Journal Of Hematology, 2021-08-01 00:00:00.0; 96(8), p. 979-988.
EPub date: 2021-05-27 00:00:00.0.
PMID: 33971040
Related Citations

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
Authors: Arushi Khurana null , Mwangi R. , Ansell S.M. , Habermann T.M. , Cerhan J.R. , Strouse C. , Link B.K. , Wang Y. , King R.L. , Macon W.R. , et al. .
Source: Blood Cancer Journal, 2021-07-17 00:00:00.0; 11(7), p. 133.
EPub date: 2021-07-17 00:00:00.0.
PMID: 34274939
Related Citations

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.
Authors: Mondello P. , Fama A. , Larson M.C. , Feldman A.L. , Villasboas J.C. , Yang Z.Z. , Galkin I. , Svelolkin V. , Postovalova E. , Bagaev A. , et al. .
Source: Blood Cancer Journal, 2021-07-15 00:00:00.0; 11(7), p. 130.
EPub date: 2021-07-15 00:00:00.0.
PMID: 34267181
Related Citations

Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
Authors: Goldman M.L. , Mao J.J. , Strouse C.S. , Chen W. , Rupji M. , Chen Z. , Maurer M.J. , Calzada O. , Churnetski M. , Flowers C.R. , et al. .
Source: Cancer, 2021-06-22 00:00:00.0; , .
EPub date: 2021-06-22 00:00:00.0.
PMID: 34157780
Related Citations

Body mass index and survival of patients with lymphoma.
Authors: Chihara D. , Larson M.C. , Robinson D.P. , Thompson C.A. , Maurer M.J. , Casulo C. , Pophali P. , Link B.K. , Habermann T.M. , Feldman A.L. , et al. .
Source: Leukemia & Lymphoma, 2021-06-14 00:00:00.0; , p. 1-8.
EPub date: 2021-06-14 00:00:00.0.
PMID: 34121594
Related Citations

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Authors: Khurana A. , Mwangi R. , Nowakowski G.S. , Habermann T.M. , Ansell S.M. , LaPlant B.R. , Link B.K. , Cerhan J.R. , Maurer M.J. , Witzig T.E. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-05-20 00:00:00.0; 39(15), p. 1641-1649.
EPub date: 2021-02-02 00:00:00.0.
PMID: 33529046
Related Citations

Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Authors: Maurer M.J. , Jakobsen L.H. , Mwangi R. , Schmitz N. , Farooq U. , Flowers C.R. , de Nully Brown P. , Thompson C.A. , Frederiksen H. , Cunningham D. , et al. .
Source: American Journal Of Hematology, 2021-05-01 00:00:00.0; 96(5), p. 599-605.
EPub date: 2021-03-18 00:00:00.0.
PMID: 33661547
Related Citations

Epidemiology of Marginal Zone Lymphoma.
Authors: Cerhan J.R. , Habermann T.M. .
Source: Annals Of Lymphoma, 2021 Mar; 5, .
EPub date: 2021-03-30 00:00:00.0.
PMID: 33829216
Related Citations

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Authors: Hartert K.T. , Wenzl K. , Krull J.E. , Manske M. , Sarangi V. , Asmann Y. , Larson M.C. , Maurer M.J. , Slager S. , Macon W.R. , et al. .
Source: Leukemia, 2021 02; 35(2), p. 522-533.
EPub date: 2020-03-05 00:00:00.0.
PMID: 32139889
Related Citations

The association of health behaviors with quality of life in lymphoma survivors.
Authors: Pophali P.A. , Larson M.C. , Rosenthal A.C. , Robinson D. , Habermann T.M. , Thanarajasingam G. , Call T. , Allmer C. , Farooq U. , Maurer M.J. , et al. .
Source: Leukemia & Lymphoma, 2021 02; 62(2), p. 271-280.
EPub date: 2020-10-13 00:00:00.0.
PMID: 33047636
Related Citations